Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of PROLOR Biotech, Inc.

Holzer Holzer & Fistel, LLC is investigating whether the directors of PROLOR Biotech, Inc. (“PROLOR” or the “Company”) PBTH complied with their fiduciary duties in approving the proposed acquisition of the Company by OPKO Health Inc. According to the Company's announcement, if the deal closes PROLOR shareholders will receive 0.9951 shares of OPKO stock for each share of PBTH owned, which values the PROLOR stock at $7 per share. The firm's investigation seeks to determine, among other things, whether the consideration to be paid to PROLOR shareholders is fair and adequate.

Current holders of PROLOR common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.